Ivermectin does not prevent progression to severe COVID-19
Feb 23, 2022
No impact on progression to severe disease was seen for high-risk patients with mild-to-moderate disease receiving ivermectin during early illness.
Abnormal ventilatory patterns common after COVID-19 infection
Dec 09, 2021
Patients with postacute sequelae of SARS-CoV-2 infection also have circulatory impairment and myalgic encephalomyelitis/chronic fatigue.
New Coronavirus Briefing e-newsletter shares content from McKnight’s and sister brands
By
Lois A. Bowers
Mar 17, 2020
To keep business leaders informed of developments related to the pandemic, Haymarket Media, the global business information company that is the parent company of McKnight’s Senior Living and McKnight’s...
Updated immunization schedule presented for adults for 2024
Jan 11, 2024
The changes include a recommendation for all adults to receive a dose of the new COVID-19 vaccine and RSV vaccination.
Amygdala and insula retraining tied to reduction in fatigue with long COVID
Jul 24, 2023
Furthermore, patients randomly assigned to the neuroplasticity program saw significant gains in energy.
Risk profile IDs COVID-19 patients who will benefit from baricitinib
Feb 26, 2024
Baricitinib plus remdesivir was linked to a reduced risk of death and progression to invasive mechanical ventilation.
COVID-19 death after menopause down with increased estrogen level
Feb 15, 2022
The risk for dying was reduced for postmenopausal women receiving hormone replacement therapy, with increased estrogen levels.
COVID-19 convalescent plasma no benefit for most patients
Feb 03, 2022
There was no association with clinical outcomes for typical patients; a heterogeneity of treatment effect sizes was seen across baseline characteristics.
Severity of acute COVID-19 tied to frequency of long COVID diagnosis
Dec 13, 2022
Female sex and previous mental health disorders and asthma were associated with long COVID, regardless of COVID-19 severity.
Study compares baricitinib to dexamethasone for COVID-19
Jun 21, 2022
Baricitinib plus remdesivir shows similar efficacy but a better safety profile than dexamethasone plus remdesivir in hospitalized adults.